2020
Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances 2020, 4: 539-545. PMID: 32045473, PMCID: PMC7013262, DOI: 10.1182/bloodadvances.2019000827.Peer-Reviewed Original ResearchMeSH KeywordsCost SavingsHospitalsHumansPurpura, Thrombotic ThrombocytopenicRetrospective StudiesRituximabConceptsThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeRituximab useAdmission dayThrombocytopenic purpuraTPE proceduresInpatient settingAutoimmune thrombotic thrombocytopenic purpuraCost of rituximabDisease flareLifelong threatPlasma exchangeHematologic emergencyInpatient costsRelapse riskSevere autoimmuneRituximabAcademic centersCost savingsHospitalPurpuraPatientsAdmissionCohortSetting
2009
The persistence and evanescence of blood group alloantibodies in men
Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009, 49: 505-512. PMID: 19040411, DOI: 10.1111/j.1537-2995.2008.02014.x.Peer-Reviewed Original ResearchConceptsBlood group alloantibodiesVeterans Affairs Medical CenterInitial negative testingTransfusion service recordsTransfusion-related alloimmunizationDuration of followHemolytic transfusion reactionsMonths of detectionFirst antibodyMale patientsTransfusion reactionsMedical CenterAlloantibodiesNegative testingAntibody detectionYear of inductionStudy designAntigenic specificityAntibodiesMilitary veteransPatientsMore yearsTwo-thirdsService recordsMen